VolitionRx Ltd (NYSE AMERICAN:VNRX) has finished a three-year long collection of blood samples taken as part of a prospective study with the University of Oxford that aims to evaluate whether the company's easy-to-use Nu.Q blood-based tests can be used to diagnose endometriosis.
The collection of the blood samples from 350 patients over a period of more than three years was led by Professors Christian Becker and Krina Zondervan, co-directors of the University of Oxford’s Endometriosis Care and Research Centre.
The Belgium-based company will now begin screening the blood samples using its Nu.Q. Assay kits and expects to report preliminary data from its investigation over the coming months.
“Volition owns patents in the detection of endometriosis using nucleosome assays and we look forward to investigating the use of Nu.Q technology in this large patient cohort,” said Dr Jake Micallef, Volition’s chief scientific officer, in a statement.
Early detection and diagnosis of endometriosis remain an important medical need for women. A leading cause of infertility, the condition can be extremely painful and is still diagnosed surgically by laparoscopy.
“We are looking forward to the results of this study which very much complements our ongoing efforts at the Oxford Endometriosis CaRe Centre of identifying non-invasive biomarkers for endometriosis which we believe will be an essential step towards improving patient diagnosis and care,” said Professor Becker in a statement.
Currently, VolitionRx develops and markets its cost-effective, easy-to-use Nu.Q blood-based tests to accurately diagnose colorectal cancer as well as a broad range of other cancers. The tests are based on VolitionRx’s Nucleosomics technology platform, which identifies and measures nucleosomes in the bloodstream or in other bodily fluid.
VolitionRx shares rose slightly on the NYSE American exchange to US$1.71.
Contact Ellen Kelleher at [email protected]